Abstract
Designing drugs against the fibroblast growth factor (FGF) pathway is complicated by the fact that there are several FGF family members with different biological activities. Blocking the hormonal FGFs causes toxicities; so, Harding et al. developed a soluble decoy receptor, FP-1039, that binds only the mitogenic FGFs. FP-1039 blocked FGF- and vascular endothelial growth factor (VEGF)-induced angiogenesis in vivo, and inhibited tumour growth in several xenograft mouse models with minimal toxicity. Xenografts of cancer cells with FGF pathway alterations were particularly sensitive to FP-1039.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.